Gaber Asmaa M, Abdel-Moneim Adel, Abdel-Reheim Eman S, Allam Gamal, Abdul-Hamid Manal, Hosni Ahmed
Molecular Physiology Division, Department of Zoology, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt.
Immunology Division, Department of Zoology, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt.
Front Pharmacol. 2025 Jul 2;16:1553992. doi: 10.3389/fphar.2025.1553992. eCollection 2025.
Hypothyroidism is a frequent endocrine health issue that is linked to adverse cardiovascular events. Accumulating evidence suggests that thyroid hormone replacement does not fully reverse the cardiovascular complications associated with the disease despite normalization of serum thyroid hormone levels, indicating a need for adjunctive, complementary, or alternative therapies. Hesperidin (HSD) has diverse pharmacological activities, however, its therapeutic potential on the crosstalk between hypothyroidism and cardiac dysfunction has not been previously reported.
This study aimed to investigate the cardioprotective efficacy of HSD on carbimazole (CMZ)-induced hypothyroidism in rats in comparison to the traditional thyroid hormone replacement therapy; levothyroxine (LT4). Male Wistar albino rats were divided into four groups: normal control (NC), CMZ (30 mg/kg), CMZ + HSD (30 mg/kg CMZ + 200 mg/kg HSD), and CMZ + LT4 (30 mg/kg CMZ + 0.045 mg/kg). All doses were given orally and daily for 9 weeks.
CMZ intake resulted in a significant decrease in thyroid hormones (THs) levels with a subsequent increase in serum thyroid stimulating hormone and cardiac enzymes activities, dyslipidemia, and body weight gain. Cardiac tissues revealed marked oxidative stress, inflammation, and structural degenerative lesions. As well, cardiac expression of miRNAs-92a and -499 was elevated while that of miRNA-21 was depleted, reflecting an interdependence between hypothyroidism and the development of cardiac dysfunction. Despite HSD and LT4 effectively alleviating the THs profile, only HSD offered substantial protection from hypothyroidism-associated cardiac inflammation and injury through its potent impact on the transcriptional miRNAs level and Nrf2/NF-κB protein expression (key regulators of the redox biomarkers and the inflammatory mediators).
HSD provides dual thyroprotective and cardioprotective effects that enhance THs bioavailability and functionality in the cardiovascular system.
甲状腺功能减退是一种常见的内分泌健康问题,与不良心血管事件相关。越来越多的证据表明,尽管血清甲状腺激素水平恢复正常,但甲状腺激素替代疗法并不能完全逆转与该疾病相关的心血管并发症,这表明需要辅助、补充或替代疗法。橙皮苷(HSD)具有多种药理活性,然而,其对甲状腺功能减退与心脏功能障碍之间相互作用的治疗潜力此前尚未见报道。
本研究旨在比较HSD与传统甲状腺激素替代疗法左甲状腺素(LT4)对卡比马唑(CMZ)诱导的大鼠甲状腺功能减退的心脏保护作用。雄性Wistar白化大鼠分为四组:正常对照组(NC)、CMZ组(30mg/kg)、CMZ+HSD组(30mg/kg CMZ+200mg/kg HSD)和CMZ+LT4组(30mg/kg CMZ+0.045mg/kg)。所有剂量均每日口服给药,持续9周。
摄入CMZ导致甲状腺激素(THs)水平显著降低,随后血清促甲状腺激素和心肌酶活性升高、血脂异常和体重增加。心脏组织显示出明显的氧化应激、炎症和结构退行性病变。此外,miRNAs-92a和-499的心脏表达升高,而miRNA-21的表达减少,这反映了甲状腺功能减退与心脏功能障碍发展之间的相互依存关系。尽管HSD和LT4有效地改善了THs水平,但只有HSD通过其对转录miRNAs水平和Nrf2/NF-κB蛋白表达(氧化还原生物标志物和炎症介质的关键调节因子)的强大影响,为甲状腺功能减退相关的心脏炎症和损伤提供了实质性保护。
HSD具有双重甲状腺保护和心脏保护作用,可提高心血管系统中THs的生物利用度和功能。